First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma By Ogkologos - March 24, 2026 321 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ILUSTRO study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Prize winning early detection research October 7, 2021 4,000 Cancer Patients Affected by Diluted Chemotherapy Doses from Crooked Pharmacist September 17, 2020 Advanced MRI could help to differentiate aggressive and slower growing prostate... February 14, 2022 Age: the forgotten cancer risk factor? May 29, 2023 Load more HOT NEWS A Combination of Trastuzumab with Gemcitabine and Cisplatin Shows Promising Activity... Spectacular Breast Cancer Awareness Calendar Showcases Survivors’ Stories, Told with Body... 27-Year-Old Fighting Stage IV Cancer Gets Hit By COVID-19 And Sepsis... Study Advances Fertility Preservation Approach for Male Cancer Survivors
